Cargando…

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation

Advanced hepatocellular carcinoma (HCC) with vascular invasion and/or extrahepatic spread and preserved liver function, according to stage C of the Barcelona Clinic Liver Cancer (BCLC) classification, has a dismal prognosis. The multi-targeted tyrosine-kinase receptor inhibitor (TKI) sorafenib is th...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Felden, Johann, Schulze, Kornelius, Gil-Ibanez, Ines, Werner, Tobias, Wege, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192519/ https://www.ncbi.nlm.nih.gov/pubmed/27916795 http://dx.doi.org/10.3390/diagnostics6040044

Ejemplares similares

Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma
por: von Felden, Johann, et al.
Publicado: (2020)

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
por: von Felden, Johann, et al.
Publicado: (2017)

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients
por: Fründt, Thorben, et al.
Publicado: (2021)

Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment
por: Fründt, Thorben W., et al.
Publicado: (2022)

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
por: von Felden, Johann, et al.
Publicado: (2017)

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
por: Kocheise, Lorenz, et al.
Publicado: (2023)

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
por: Fründt, Thorben, et al.
Publicado: (2022)

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
por: Krause, Jenny, et al.
Publicado: (2020)

Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma
por: von Felden, Johann, et al.
Publicado: (2018)

Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
por: Kim, Bo Hyun, et al.
Publicado: (2021)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review
por: Zhang, Lan, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Targeted agents for second-line treatment of advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2019)

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
por: Piñero, Federico, et al.
Publicado: (2020)

Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update
por: Prabhash, Kumar
Publicado: (2019)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma
por: Rimassa, Lorenza, et al.
Publicado: (2020)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines
por: Jogi, Soumya, et al.
Publicado: (2020)

Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
por: Pathak, Surabhi, et al.
Publicado: (2021)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
por: De Luca, Emmanuele, et al.
Publicado: (2020)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
por: Qin, He-nan, et al.
Publicado: (2022)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options
por: Meloni, Seema T, et al.
Publicado: (2017)

Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone‐Dependent Release of Circulating Tumor DNA
por: Labgaa, Ismail, et al.
Publicado: (2021)

Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond
por: Feng, Maple Ye, et al.
Publicado: (2022)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q6eduvn0tll1aptt8455qa8vjo